Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1618 1632 1671 1672
This examiner grants 67% of resolved cases
Examiner Cornelius operates within Tech Center 1600 and Art Unit 1600, where she has managed 6 resolved cases. Her allowance rate of 66.7% suggests a moderate path to grant for applicants in this biotechnology and organic chemistry domain. However, the median days to allowance of 1045 indicates a lengthy prosecution timeline. This duration suggests that even with a majority of cases being allowed, the process requires significant time and persistence from the applicant.
A notable data point is the interview lift of 0.0%. This figure indicates that conducting an interview with this examiner has not historically increased the probability of receiving an allowance. Practitioners should weigh the time investment of an interview against this lack of statistical benefit when developing a strategy for the 6 resolved cases currently on record. Given the 66.7% allowance rate, focusing on high-quality written responses and precise claim amendments may be a more effective use of resources than seeking verbal negotiation. The 1045-day median pendency should also be factored into long-term portfolio planning for applications assigned to this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18277873 | NOVEL BACTERIOPHAGE HAVING CLOSTRIDIUM PERFRINGENS-SPECIFIC BACTERICIDAL EFFECT AND ANTIBACTERIAL COMPOSITION COMPRISING SAME | Final Rejection | CJ CheilJedang Corporation |
| 18278878 | NOVEL BACTERIOPHAGE HAVING CLOSTRIDIUM PERFRINGENS-SPECIFIC BACTERICIDAL EFFECT AND ANTIBACTERIAL COMPOSITION COMPRISING SAME | Final Rejection | CJ CHEILJEDANG CORPORATION |
| 18571367 | CAPSID VARIANTS AND METHODS OF USING THE SAME | Final Rejection | DYNO THERAPEUTICS, INC. |
| 17997791 | MODIFIED ADENO-ASSOCIATED VIRUS VECTORS THAT EVADE NEUTRALIZING ANTIBODIES AND USES THEREOF | Final Rejection | The University of North Carolina at Chapel Hill |
| 18654961 | VIRAL ANTIGEN DISPLAY COMPOSITIONS AND METHODS | Non-Final OA | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 18727308 | CIRCULAR RNA VACCINES AGAINST SARS-COV-2 VARIANTS AND METHODS OF USE THEREOF | Non-Final OA | Peking University |
| 18511416 | Virus-like Particles with Programmable Tropism and Methods of Use Thereof for Delivery to Cells | Non-Final OA | The General Hospital Corporation |
| 18277425 | NOVEL DRUGGABLE REGIONS IN THE HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN B POLYPEPTIDE AND METHODS OF USE THEREOF | Non-Final OA | Pfizer Inc. |
| 18350357 | FOAM VACCINATION OF AVIANS | Non-Final OA | UNIVERSITY OF DELAWARE |
| 18256481 | METHODS OF PURIFYING ADENOVIRUS | Non-Final OA | ASTRAZENECA UK LIMITED |
| 18557406 | MOLECULAR SIGNATURES OF LONG-TERM COVID-19 AND TREATMENT THEREOF | Non-Final OA | FRED HUTCHINSON CANCER CENTER |
| 18556744 | ENGINEERING BIOLOGICS TO HPV ONCOPROTEINS | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18557396 | PREFUSION-STABILIZED LASSA VIRUS GLYCOPROTEIN COMPLEX AND ITS USE | Non-Final OA | The U.S.A., as represented by the Secretary, Department of Health and Human Services |
| 18262073 | Therapeutic Viral Vaccine | Final Rejection | GlaxoSmithKline Biologicals SA |
| 18708467 | PREDICTING COVID-19 ANTIBODIES AMONG SURVIVORS WITH DEEP RNA SEQUENCING | Non-Final OA | Rhode Island Hospital |
| 18564621 | Insect cell production of parvoviral vectors with modified capsid proteins | Non-Final OA | uniQure biopharma B.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy